ストックスクリーナーアプリを入手
5.75
1.03%
-0.06
アフターアワーズ：
5.76
0.010
+0.17%
前日終値:
$5.81
開ける：
$5.85
24時間の取引高:
47,589
Relative Volume:
0.52
時価総額：
$641.06M
収益：
$117.05M
当期純損益:
$-3.71M
株価収益率:
-73.81
EPS:
-0.0779
ネットキャッシュフロー:
$1.67M
1週間 パフォーマンス:
-3.20%
1か月 パフォーマンス:
-12.75%
6か月 パフォーマンス:
-28.92%
1年 パフォーマンス:
-18.44%
1日の値動き範囲:
$5.62
$5.884
1週間の範囲:
$5.62
$6.27
52週間の値動き範囲:
$5.44
$9.42
Gyre Therapeutics Inc Stock (GYRE) Company Profile
名前
Gyre Therapeutics Inc
セクター
電話
(858) 284-0115
住所
12730 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
5.75 | 683.43M | 117.05M | -3.71M | 1.67M | -0.0779 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-10 | 開始されました | Jefferies | Buy |
| 2025-08-26 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-11 | 開始されました | Noble Capital Markets | Outperform |
| 2021-04-29 | 再開されました | Stephens | Overweight |
| 2021-02-10 | 開始されました | Piper Sandler | Overweight |
| 2020-05-21 | 開始されました | Raymond James | Outperform |
| 2019-01-04 | 開始されました | Oppenheimer | Outperform |
| 2018-02-12 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-12-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 開始されました | Chardan Capital Markets | Buy |
| 2017-06-06 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-06-30 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
Gyre Therapeutics Inc (GYRE) 最新ニュース
Gyre Therapeutics Inc (GYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gyre Therapeutics Inc (GYRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gyre Therapeutics Inc (GYRE) Balance Sheet - TradingKey
Gyre Therapeutics Inc (GYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gyre Therapeutics Inc (GYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gyre Therapeutics Inc (GYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GYRE|Gyre Therapeutics Inc|Price:6.110|Chg%:+0.170 - TradingKey
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics Inc (GYRE) Income Statement - TradingKey
TradingKey - TradingKey
Cash flow from financing activities of Gyre Therapeutics Inc – GETTEX:L9S - TradingView
Gyre Therapeutics, Inc. Revenue Breakdown – NASDAQ:GYRE - TradingView
Gyre Therapeutics Inc (GYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Return on assets % of Gyre Therapeutics Inc – MUN:L9S - TradingView
Discontinued operations of Gyre Therapeutics Inc – MUN:L9S - TradingView
Return on assets % of Gyre Therapeutics Inc – GETTEX:A3EE5F - TradingView
Gyre Therapeutics Inc Statistics – MUN:L9S - TradingView
Gyre Therapeutics Inc Statistics – GETTEX:A3EE5F - TradingView
Gyre Therapeutics, Inc. (L9S.F) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Gyre Therapeutics Strengthens Board with New Director Appointments - The Globe and Mail
Gyre Therapeutics appoints three directors to board By Investing.com - Investing.com Nigeria
Gyre Therapeutics appoints three directors to board - Investing.com
Gyre Therapeutics (Nasdaq: GYRE) adds three directors, expanding expertise - Stock Titan
Gyre Therapeutics Appoints Three New Members to its Board of Directors - The Manila Times
Gyre Therapeutics, Inc. Announces Board and Committee Changes, Effective August 1, 2026 - marketscreener.com
Gyre Therapeutics Inc. (GYRE) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise in Pre-Revenue StageNew Analyst Coverage - dars.gov.et
Gyre Therapeutics (GYRE) Registration filing Summary - Quartr
Gyre Adds Director With Drug Development Experience Across China, Japan - Stock Titan
Cullgen $300M all-stock deal expands Gyre Therapeutics (Nasdaq: GYRE) - Stock Titan
Yue Xiong Net Worth (2026) - GuruFocus
Jialiang (nmn) Wang Net Worth (2026) - GuruFocus
Joshua Benjamin Bergmann Net Worth (2026) - GuruFocus
Form S-3/A Gyre Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Gyre Therapeutics (Nasdaq: GYRE) details 31.3M-share resale and China risks - Stock Titan
GYRE Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline AdvancesEPS Guidance Update - po-news-eg.net
GYRE Q1 2026 Earnings: Narrower-than-expected loss as EPS beats estimates; stock slipsEarnings Surprise Report - DonanımHaber
Gyre Therapeutics Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Absence; Stock DeclinesReturn On Capital - DonanımHaber
Gyre Therapeutics highlights pipeline progress as investors watch fibrosis focus - ad-hoc-news.de
GYREGyre Therapeutics Inc Options - Finviz
Form 4 Gyre Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
Gyre Therapeutics (GYRE) director awarded 40,000 stock options at $5.95 - Stock Titan
Director Dan Weng receives 40,000-share option grant at GYRE (NASDAQ: GYRE) - Stock Titan
GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
US High Growth Tech Stocks to Watch - simplywall.st
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value Benchmark - marketscreener.com
GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm - ACCESS Newswire
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value-Defensive Index - marketscreener.com
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Defensive Index - marketscreener.com
Price to earnings forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Price to earnings forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView
Gyre Therapeutics Inc (GYRE) 財務データ
収益
当期純利益
現金流量
EPS
Gyre Therapeutics Inc (GYRE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Option Exercise |
0.75 |
3,000 |
2,250 |
703,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 18 '26 |
Option Exercise |
0.75 |
3,000 |
2,250 |
703,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 10 '26 |
Sale |
6.24 |
5,000 |
31,200 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 18 '26 |
Sale |
6.35 |
3,000 |
19,050 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Sale |
6.15 |
3,000 |
18,450 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 11 '26 |
Option Exercise |
0.75 |
2,800 |
2,100 |
702,800 |
| Ye Weiguo | Chief Operating Officer |
Jun 11 '26 |
Sale |
6.17 |
2,800 |
17,276 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Option Exercise |
0.75 |
14,500 |
10,875 |
714,500 |
| Ye Weiguo | Chief Operating Officer |
Jun 10 '26 |
Option Exercise |
0.75 |
6,418 |
4,814 |
706,418 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Sale |
6.14 |
14,500 |
89,030 |
700,000 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):